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Abstract
Transgenic mice overexpressing IFN-g in the epidermis develop an inflammatory skin disease
resembling cutaneous lupus erythematosus shortly after birth. By 3 months of age, most
female transgenics develop a lupus-like syndrome characterised by production of IgG anti-
dsDNA, antihistone and antinucleosome autoantibodies. The autoantibodies are
nephritogenic, with one-third of females developing a severe immune complex mediated
glomerulonephritis. Analysis of these transgenics suggests that pathogenic autoantibodies
arise via an antigen-driven T-cell-dependent mechanism with apoptotic keratinocytes acting
as a potential source of autoantigen. The mechanism of autoantibody production in IFN-g
transgenics may be relevant to human lupus and is consistent with a central role for
cutaneous T cells in the pathogenesis of systemic lupus erythematosus in man.
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ANA = antinuclear antibodies; APC = antigen presenting cell; CLA = cutaneous lymphocyte antigen; CLE = cutaneous lupus erythematosus; DC =
dendritic cell; ICAM = intracellular adhesion molecule; MHC = major histocompatibility antigen; SIS = skin immune system; SLE = systemic lupus
erythematosus.
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Introduction
Epidemiological evidence implies that systemic lupus ery-
thematosus (SLE) is caused by the action of an environmen-
tal agent (or agents) on genetically susceptible individuals
[1]. Although the nature of these environmental factors
remains unknown, the ‘downstream’ mechanisms involved
in pathogenic autoantibody production are being defined.
The evidence from both patients and animal models of the
disease strongly suggests that antinuclear antibodies (ANA)
arise via a classical T-cell-dependent immune response [2].
Furthermore, circumstantial evidence implies that the
autoantigens driving this response are nucleoprotein
complexes released during apoptosis [3]. The ANA pro-
duced are largely responsible for the widespread tissue
damage characteristic of the syndrome [4].
The essential role of IFN-g in the pathogenesis of immune
complex mediated end organ disease has been firmly
established in several experimental models [5]. However,
there is some evidence that IFN-g may also play a role
earlier in the disease process, specifically in the initiation
of ANA production. For example, the emergence of SLE,
with de novo anti-dsDNA antibody production, has been
described in some patients receiving systemic treatmentArthritis Research    Vol 2 No 6 Seery
with IFN-g, suggesting that excess amounts of the
cytokine in susceptible individuals can trigger an auto-
immune response relevant to SLE [6]. This contention is
supported by results from transgenic mice expressing
IFN-g under the control of the involucrin promoter [7].
IFN-g g transgenic mice develop a lupus-like
syndrome
Involucrin is a component of the keratinocyte cell envelope
and its expression is essentially limited to the suprabasal
layers of stratified squamous epithelia [8]. In order to study
the role of IFN-g in the pathogenesis of inflammatory skin
disease, we generated transgenic mice expressing the
cytokine under the influence of the involucrin promoter [7].
Transgenics have markedly elevated levels of IFN-g protein
in the skin and, shortly after birth, develop an inflammatory
skin lesion characterised histologically by a dermal
mononuclear infiltrate [7]. Most female transgenics over
3 months of age also produce high levels of IgG anti-
nucleosome, antihistone and anti-dsDNA antibodies. The
autoantibodies are nephritogenic, with at least one-third of
females developing a severe immune complex mediated
glomerulonephritis. Autoantibodies against extractable
nuclear antigens are rarer but are present in some female
animals. Male IFN-g transgenics do not develop the lupus
phenotype [9].
IFN-g has been overexpressed in several extracutaneous
tissues, in all cases resulting in the development of only
organ specific autoimmunity [10,11]. Taken with our find-
ings, this implies that the skin immune system (SIS) in
females has specific properties that, under the wrong cir-
cumstances, can trigger the lupus autoimmune response.
How does the SIS generate ANA? 
The mechanism of ANA production in IFN-g g
transgenic mice
By generating IFN-g transgenic mice congenitally deficient
in ab T cells, we showed that autoantibody production
and end organ damage in this model are completely
dependent on the presence of functional ab T cells [12],
strongly implying that, as in the human disease, the ANA
of IFN-g transgenics arise via a classical antigen-driven
T-cell-dependent immune response. What is the source of
self-nuclear antigen in these animals and how is it pre-
sented to autoreactive T cells?
IFN-g is a potent stimulus of keratinocyte apoptosis, and
both the basal layer of the epidermis and the dermis of
IFN-g transgenics contain large amounts of terminal
deoxynucleotidyl transferase-mediated dUTP nick end-
labelling positive material [12]. This material is a likely
source of autoantigen in these animals as the self-antigens
of SLE are known to cluster in the surface blebs of apop-
totic keratinocytes [13]. IFN-g can stimulate apoptosis by
a number of mechanisms; facilitation of Fas/FasL inter-
actions, however, appears to be of particular relevance in
keratinocytes [14]. IFN-g upregulates keratinocyte Fas
expression and cells in the epidermal basal layer of IFN-g
transgenics strongly express Fas (Seery et al, unpublished
observations). Furthermore, immunocytes expressing FasL
are present in the dermal infiltrate (Seery et al, unpub-
lished observations). It is therefore possible that IFN-g
facilitates a productive interaction between these ligands
leading to keratinocyte apoptosis. The fact that epidermal
apoptosis in these animals is sensitive to inhibition with
the pan-caspase inhibitor carbobenzoxy-valyl-alanyl-
aspartyl-(beta-o-methyl)-fluoromethylketone (Seery et al,
unpublished observations) supports this concept as Fas
independent mechanisms of IFN-g induced apoptosis are
augmented by this agent [15].
Histological examination of the skin of IFN-g transgenics
suggests two possible mechanisms by which apoptotic
material may be presented to autoreactive T cells. First,
basal cells in IFN-g transgenics strongly express major his-
tocompatibility antigen (MHC) class II and intracellular
adhesion molecule (ICAM) [7], and there is evidence that
under some circumstances keratinocytes may act as
antigen presenting cells (APC) [16,17]. We could not,
however, demonstrate B7 expression in the epidermis of
these animals and, in the absence of such costimulatory
molecules, presentation of antigen by keratinocytes may be
tolerogenic (vide infra) [17]. An alternative mechanism of
autoreactive T-cell activation is suggested by analysis of
epidermal dendritic cell (DC) distribution in IFN-g transgen-
ics. There is evidence that DCs migrate from inflamed skin
to the draining lymph nodes in these animals [7]. Further-
more, remnants of apoptotic cells are known to be taken up
by DCs [3]. It seems likely that apoptotic material carried
from the skin by these professional APC is presented to
autoreactive T cells in the lymph nodes draining the skin,
with subsequent activation of B-cell ANA production [12].
IFN-g g in human SLE: a central role for
cutaneous T cells?
Cutaneous lupus erythematosus (CLE) shares many fea-
tures with IFN-g induced skin disease: a dermal mono-
nuclear infiltrate with FasL-positive immunocytes present
[18], keratinocyte ICAM, MHC and Fas expression [19,20],
abundant epidermal apoptotic cells (‘sunburn cells’) and
loss of DCs from the epidermis [21,22]. Interestingly, CLE
is a prominent feature of iatrogenic IFN-g induced lupus in
man [6]. If IFN-g is involved in triggering CLE, this implies
that activated T cells (as the major in vivo source of the
cytokine) may play a central role in the pathogenesis of the
naturally occurring disease. The fact that refractory CLE
responds to CD4+ T-cell depleting antibodies is at least
consistent with this possibility [23]. Cutaneous lymphocyte
antigen (CLA)-positive T cells have been implicated in the
pathogenesis of diverse skin lesions including psoriasis,
lichen planus and alopecia areata [24]. CLE as a T-cell-http://arthritis-research.com/content/2/6/437
mediated disease raises some interesting possibilities
because the lesion would be self-amplifying and would
provide a potential site of ANA production (Figure 1). A
central role for cutaneous T cells in lupus pathogenesis
could also explain the apparently contradictory therapeutic
response of the systemic disease to UVA irradiation of the
skin [25]. Activated T cells are sensitive to UVA induced
apoptosis, whereas higher energy UVB could aggravate
the systemic disease by inducing keratinocyte apoptosis
[26]. There are, however, a number of obvious objections
to the hypothesis outlined in Figure 1. Although skin
disease is common in SLE, it is by no means universal [27].
Cases without clinically apparent cutaneous involvement
presumably have an alternative source of apoptosis derived
antigen. Nevertheless, it is worth noting that, in murine
lupus models without clinically overt skin lesions, histologi-
cal examination can reveal subclinical abnormalities. Fur-
thermore, irradiation of the skin in these animals can affect
the systemic disease process [28]. 
Conclusion
Transgenic models of human disease have a number of
limitations. Tissues generally have a limited number of
ways in which they respond to insult. Several different
types of noxious agents may give rise to a similar patho-
logical picture without necessarily bearing an aetiological
relationship to the naturally occurring human disease.
However, data from IFN-g transgenic mice suggest that
the SIS is at least capable of playing the central role in
SLE pathogenesis. The fact that the lupus-like syndrome
in these animals mirrors the human disease in arising via a
classical T-cell-dependent mechanism may make it a
useful model in which to study specific immunomodulatory
therapies.
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